A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-na?ve patients with metastatic or recurrent squamous cell carcinoma of the esophagus

Dae Ho Lee; Heung Tae Kim; Ji-Youn Han; Sung Young Lee; Sung Jin Yoon; Hyae Young Kim; Jin Soo Lee

首页> 外文期刊>Cancer Chemotherapy and Pharmacology >A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-na?ve patients with metastatic or recurrent squamous cell carcinoma of the esophagus

【24h】

A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-na?ve patients with metastatic or recurrent squamous cell carcinoma of the esophagus

机译：每周改良伊立替康和顺铂治疗食管癌初发转移性或复发性食管鳞状细胞癌的II期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

This phase II study assessed the efficacy and toxicity profile of a modified weekly irinotecan and cisplatin for chemotherapy-na?ve patients with metastatic/recurrent esophageal squamous cell carcinoma (SQCC).

机译：这项II期研究评估了改良的每周伊立替康和顺铂对未进行过化疗的转移性/复发性食管鳞状细胞癌（SQCC）患者的疗效和毒性。

著录项

来源
《Cancer Chemotherapy and Pharmacology》 |2008年第1期|83-88|共6页
作者
Dae Ho Lee; Heung Tae Kim; Ji-Youn Han; Sung Young Lee; Sung Jin Yoon; Hyae Young Kim; Jin Soo Lee;
展开▼
作者单位

Division of Oncology Department of Internal Medicine Asan Medical Center University of Ulsan Seoul South Korea;

Center for Lung Cancer Research Institute and Hospital National Cancer Center 809 Madu-dong Ilsandong-gu Goyang Gyeonggi 411-769 South Korea;

Center for Lung Cancer Research Institute and Hospital National Cancer Center 809 Madu-dong Ilsandong-gu Goyang Gyeonggi 411-769 South Korea;

Center for Lung Cancer Research Institute and Hospital National Cancer Center 809 Madu-dong Ilsandong-gu Goyang Gyeonggi 411-769 South Korea;

Center for Lung Cancer Research Institute and Hospital National Cancer Center 809 Madu-dong Ilsandong-gu Goyang Gyeonggi 411-769 South Korea;

Center for Lung Cancer Research Institute and Hospital National Cancer Center 809 Madu-dong Ilsandong-gu Goyang Gyeonggi 411-769 South Korea;

Center for Lung Cancer Research Institute and Hospital National Cancer Center 809 Madu-dong Ilsandong-gu Goyang Gyeonggi 411-769 South Korea;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Irinotecan; Cisplatin; Esophageal squamous cell carcinoma; Modified schedule;

机译：伊立替康;顺铂;食管鳞状细胞癌;修改时间表;

相似文献

外文文献
中文文献
专利

1. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naive patients with metastatic or recurrent squamous cell carcinoma of the esophagus. [J] . Lee DH, Kim HT, Han JY, Cancer chemotherapy and pharmacology. . 2008,第1期

机译：改良的每周依立替康和顺铂治疗食管癌转移或复发的初治化疗患者的II期试验。
2. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group [J] . GilbertJ., LeeJ.W., ArgirisA., Head and neck: Journal for the sciences and specialities of the head and neck . 2013,第7期

机译：蛋白酶体抑制剂PS-341（硼替佐米）联合伊立替康或单独PS-341的II期2臂试验，在局部复发或转移性头颅鳞癌患者中，在病情发展时加用伊立替康颈部（E1304）：东方合作肿瘤小组的一项试验
3. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial [J] . Stefano Kim, Bruno Buecher, Thierry André, BMC Cancer . 2020,第1期

机译：atezolizumab加修饰的多西紫杉醇 - 顺铂-5-氟尿嘧啶（MDCF）方案与MDCF在转移或不可切除的局部晚期复发性肛鳞细胞癌中的患者：随机的非比较期II稀缺的Gercor试验
4. Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards? [C] . Ana M. Molina Genitourinary Cancers Symposium . 2012

机译：在转移性肾细胞癌中设计III期试验：新标准是什么？
5. E3 Ligase Identified by Differential Display (EDD) Enhances Cell Survival and Cisplatin Resistance in Epithelial Ovarian Cancer and Oral Squamous Cell Carcinoma. [D] . Bradley, Amber Thompson. 2014

机译：通过差异显示（EDD）鉴定的E3连接酶可增强上皮性卵巢癌和口腔鳞状细胞癌的细胞存活率和顺铂耐药性。
6. Phase II 2-arm trial of the proteasome inhibitor PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): A trial of the Eastern Cooperative Oncology Group [O] . Jill Gilbert, Ju Whei Lee, Athanassios Argiris, -1

机译：II 2-ARM试验蛋白酶体抑制剂PS-341（Bortezomib）与Irinotecan或PS-341组合然后在患有头部局部复发或转移鳞状细胞癌的患者的进展时加入伊立替康。颈部（E1304）：东方合作肿瘤组的试验
7. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck [O] . Jill Gilbert, Anthony Cmelak, Yu Shyr, 2008

机译：伊替康伊替康加铂铂的第二阶段试验患者患者的头部和颈部复发或转移鳞状癌

A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-na?ve patients with metastatic or recurrent squamous cell carcinoma of the esophagus

摘要

著录项

相似文献

相关主题

期刊订阅